Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease
News Mar 05, 2009
Serentis has announced that it has started a phase II clinical trial in pruritus associated with atopic dermatitis (AD), a type of eczema. Pruritus, more commonly known as itch, is a major symptom of AD. The lack of effective treatments of pruritus has been identified as a major unmet medical need for patients with AD.
The phase II, double blind, vehicle-controlled cross-over study is designed to determine the anti-pruritic efficacy, safety and local dermal toleration of SRD174 cream in patients with AD. The study is being conducted in 12 sites in the US.
Tim Sharpington, Serentis’ Chief Executive Officer said, “SRD174 is an innovative product with the potential to address a significant unmet need in the treatment of dermatological conditions. The initiation of this phase II study is an important milestone in the development of our clinical pipeline.”
Results from the trial are expected later in the autumn of 2009.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018